Life Science

A potent, selective, orally bioavailable inhibitor of ACAT-1 (IC₅₀ = 73 nM).

A potent, selective, orally bioavailable inhibitor of ACAT-1 (IC₅₀ = 73 nM).

An inhibitor of class I HDACs with IC50 values of 0.9, 0.

An inhibitor of class I HDACs with IC50 values of 0.9, 0.

An inhibitor of class I HDACs with IC50 values of 0.9, 0.

A prostacyclin analog that is orally active with prolonged availability in vivo, having a terminal half-life in plasma of one hour inhibits the pro-inflammatory actions of certain leukocytes, suppresses cardiac fibrosis, and blocks mitogenesis of

A prostacyclin analog that is orally active with prolonged availability in vivo, having a terminal half-life in plasma of one hour inhibits the pro-inflammatory actions of certain leukocytes, suppresses cardiac fibrosis, and blocks mitogenesis of

A prostacyclin analog that is orally active with prolonged availability in vivo, having a terminal half-life in plasma of one hour inhibits the pro-inflammatory actions of certain leukocytes, suppresses cardiac fibrosis, and blocks mitogenesis of

A corticosteroid prodrug that is converted to its active form, des-CIC, a glucocorticoid receptor agonist (Ki = 0.31 nM) used to ameliorate symptoms of airway inflammatory diseases.

A corticosteroid prodrug that is converted to its active form, des-CIC, a glucocorticoid receptor agonist (Ki = 0.31 nM) used to ameliorate symptoms of airway inflammatory diseases.

A corticosteroid prodrug that is converted to its active form, des-CIC, a glucocorticoid receptor agonist (Ki = 0.31 nM) used to ameliorate symptoms of airway inflammatory diseases.

A corticosteroid prodrug that is converted to its active form, des-CIC, a glucocorticoid receptor agonist (Ki = 0.31 nM) used to ameliorate symptoms of airway inflammatory diseases.